Corporate News: Altimmune Inc. (ALT)
Market Performance (24‑hour Period Ending 04:58 PM CET, Tuesday 20 Oct 2026)
- Stock Price: USD 2.28
- Trading Activity: 1.36 % increase
- Volume: USD 5.8 million traded
- Shares Outstanding: 194.5 million
- Market Capitalization: USD 427.9 million
- Year‑to‑Date Change: Down 31.8 % since the end of September 2026
- Simple Moving Average (200 days): USD 3.37
- 52‑Week Range: High USD 6.44 (23 Jan 2026); Low USD 2.17 (16 Oct 2026)
Recent Scientific and Regulatory Developments
- The Liver Meeting 2026 (American Association for the Study of Liver Diseases)
- Altimmune presented new data on pemvidutide, an investigational peptide targeting metabolic dysfunction‑associated steatohepatitis (MASH).
- A 48‑week Phase 2b study showed concurrent improvements in liver fibrosis and inflammation across multiple non‑invasive measures.
- Gastrointestinal tolerability was favorable, with fewer discontinuations relative to placebo.
- Pre‑clinical Findings
- A hamster model demonstrated a significant reduction in alcohol consumption, supporting research into alcohol‑related liver conditions.
- Phase 3 PERFORMA Trial
- Initiated in July 2026, the trial will assess pemvidutide’s efficacy in MASH patients.
- Positive Phase 2 Topline Data
- Recent topline results from Phase 2 studies in alcohol use disorder and alcohol‑associated liver disease were encouraging.
- Pipeline Expansion
- Development of a dual glucagon/GLP‑1 agonist aimed at reducing liver fat, inflammation, and fibrosis.
- The FDA has granted Fast Track and Breakthrough Therapy designations for key indications.
Related Stock Performance (Past 24 Hours)
| Symbol | Change | Current Price | Market Cap (USD mn) | Additional Metrics |
|---|---|---|---|---|
| FAC (Factorial Energy) | +1.47 % | 4.77 | 509.4 | — |
| BWFG (Bankwell) | –0.88 % | 66.23 | 509.2 | P/E = 12.13 |
| TITN (Titan Machinery) | –1.26 % | 22.36 | 509.1 | — |
| TCMD (Tactile I) | +0.93 % | 23.11 | 510.1 | P/E = 21.04 |
| DRUG.CN (Bright Minds Biosciences) | +2.08 % | 57.48 CAD | 720.4 | — |
- Tactile I (TCMD) announced that it will release third‑quarter fiscal year 2026 results after the market closes on Monday, 2 Nov 2026.
- A conference call and Q&A will be held at 5:00 p.m. Eastern Time.
- Investors may join by phone or via a live webcast on the company’s investor‑relations website; a replay will be available for two weeks.
Company Overview
Altimmune, Inc. is a clinical‑stage biopharmaceutical company listed on Nasdaq. The firm focuses on peptide‑based therapeutics for obesity, non‑alcoholic fatty liver disease (NASH), chronic hepatitis B, and other liver disorders. Altimmune serves patients and healthcare professionals worldwide. For further information, visit the company’s website at www.altimmune.com .
